These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34214002)

  • 1. A patent review of MALT1 inhibitors (2013-present).
    Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
    Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
    Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
    PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based covalent inhibitors of MALT1 paracaspase.
    Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
    Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
    Front Immunol; 2019; 10():1898. PubMed ID: 31474984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function and targeting of MALT1 paracaspase in cancer.
    O'Neill TJ; Tofaute MJ; Krappmann D
    Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
    Mempel TR; Krappmann D
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
    Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
    J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
    Demeyer A; Staal J; Beyaert R
    Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells.
    Biswas S; Chalishazar A; Helou Y; DiSpirito J; DeChristopher B; Chatterjee D; Merselis L; Vincent B; Monroe JG; Rabah D; Long AJ
    Front Immunol; 2022; 13():875320. PubMed ID: 35615349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
    Martin K; Junker U; Tritto E; Sutter E; Rubic-Schneider T; Morgan H; Niwa S; Li J; Schlapbach A; Walker D; Bigaud M; Beerli C; Littlewood-Evans A; Rudolph B; Laisney M; Ledieu D; Beltz K; Quancard J; Bornancin F; Zamurovic Ribrioux N; Calzascia T
    Front Immunol; 2020; 11():745. PubMed ID: 32425939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
    Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
    Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Probes for Profiling of MALT1 Protease Activity.
    Verhelst SHL; Prothiwa M
    Chembiochem; 2023 Nov; 24(21):e202300444. PubMed ID: 37607867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
    Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
    Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
    Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
    Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
    FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
    Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
    Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.
    Martin K; Touil R; Kolb Y; Cvijetic G; Murakami K; Israel L; Duraes F; Buffet D; Glück A; Niwa S; Bigaud M; Junt T; Zamurovic N; Smith P; McCoy KD; Ohashi PS; Bornancin F; Calzascia T
    J Immunol; 2019 Dec; 203(11):2791-2806. PubMed ID: 31659015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.
    Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S
    Eur J Immunol; 2018 Oct; 48(10):1728-1738. PubMed ID: 30025160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.
    Govender L; Mikulic J; Wyss JC; Gaide O; Thome M; Golshayan D
    Front Immunol; 2020; 11():576651. PubMed ID: 33042160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
    Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
    Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.